Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Sellas Life Sciences Group
Dana-Farber Cancer Institute
The Lymphoma Academic Research Organisation
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
CellCentric Ltd.
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital of Soochow University
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Sumitomo Pharma America, Inc.
Institute of Hematology & Blood Diseases Hospital, China
The First Affiliated Hospital of Soochow University
Therapeutic Advances in Childhood Leukemia Consortium
Navy General Hospital, Beijing
University of Virginia